ConductScience.org, home

Paper5779733

Control of pseudomonas infection in burns by silver sulfadiazine.

Fox CL and 2 others. Surg Gynecol Obstet, 1969. Cited by 123 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Control of pseudomonas infection in burns by silver sulfadiazine. Papers, record 5779733. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5779733

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Control of pseudomonas infection in burns by silver sulfadiazine.
PubMed
Journal
Surg Gynecol Obstet
PubMed
Year
1969
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
123
iCite
Revised in PubMed
2013-11-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fox CL JrC L
2Rappole BWB W
3Stanford WW

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BurnsMajor topic
Pseudomonas InfectionsMajor topic
SilverMajor topic
SulfadiazineMajor topic
Adult
Animals
Cephalothin
DNA
DNA, Bacterial
Female
Guinea Pigs
Humans
Mice
Military Medicine
New York
Ointments
Protein Binding
Vietnam

Source PubMed

Download CSV of topics

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.

PMIDTitleJournalYearIn PapersSource
31194776Delivery of silver sulfadiazine and adipose derived stem cells using fibrin hydrogel improves infected burn wound regeneration.PLoS One2019https://conductscience.org/library/papers/31194776PubMed
27642339Effects of Silver Sulphadiazine on Production of Extracellular Proteins by Strains of Staphylococcus Aureus Isolated from Burns Wound.Iran J Pharm Res2016https://conductscience.org/library/papers/27642339PubMed
23162237A comparative study of the effect of different topical agents on burn wound infections.Indian J Plast Surg2012https://conductscience.org/library/papers/23162237PubMed
19810827Emerging infections in burns.Surg Infect (Larchmt)2009https://conductscience.org/library/papers/19810827PubMed
19060724Concurrent in vitro release of silver sulfadiazine and bupivacaine from semi-interpenetrating networks for wound management.J Burn Care Res2009https://conductscience.org/library/papers/19060724PubMed
18730435New advances in the topical treatment of burns.Calif Med1970https://conductscience.org/library/papers/18730435PubMed
18165888Chitosan composite films. Biomedical applications.J Mater Sci Mater Med2008https://conductscience.org/library/papers/18165888PubMed
17377758[Effector molecules of the innate immune system for treatment of wound infections].Chirurg2007https://conductscience.org/library/papers/17377758PubMed
16657620Specificity of deoxyribonucleic Acid intercalating compounds in the control of phenylalanine ammonia lyase and pisatin levels.Plant Physiol1971https://conductscience.org/library/papers/16657620PubMed
15973442Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections.Gene Ther2005https://conductscience.org/library/papers/15973442PubMed
15825409Mechanism of silver sulfadiazine action on burn wound infections.Antimicrob Agents Chemother1974https://conductscience.org/library/papers/15825409PubMed
12019098Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/12019098PubMed
7574524Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7574524PubMed
5000382Control of infection with gram-negative bacteria in patients at special risk.Proc R Soc Med1971https://conductscience.org/library/papers/5000382PubMed
4986877Mechanism of prophylaxis by silver compounds against infection of burns.Br Med J1970https://conductscience.org/library/papers/4986877PubMed
4791493Silver sulfadiazine: in vitro antibacterial activity.Antimicrob Agents Chemother1973https://conductscience.org/library/papers/4791493PubMed
4677596Silver sulfadiazine: interaction with isolated deoxyribonucleic acid.Antimicrob Agents Chemother1972https://conductscience.org/library/papers/4677596PubMed
4597116Silver sulfadiazine: effect on the growth and metabolism of bacteria.Antimicrob Agents Chemother1972https://conductscience.org/library/papers/4597116PubMed
4208294Silver sulfadiazine: effect on the ultrastructure of Pseudomonas aeruginosa.Antimicrob Agents Chemother1973https://conductscience.org/library/papers/4208294PubMed
3524422Mechanism of resistance to silver ions in Klebsiella pneumoniae.Antimicrob Agents Chemother1986https://conductscience.org/library/papers/3524422PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/5779733

GET https://conductscience.org/api/papers/v1/5779733/cited_by?page=2